Merger and Acquisition (M&A) Trends in Pharma – Q3 2026
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the merger and acquisition (M&A) activity in Q3 2026 in the Pharma sector.
Scope
This report provides an overview of M&A activity globally in Q3 2026 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q3 2026 in the Pharma sector.
Key Highlights
In Q3 2026, global pharma M&A value fell 49% quarter over quarter to $51.9 billion in Q3 2026. Deal volume dipped 1.4% to 137 transactions. Oncology emerged as the leading therapeutic area recording 45 deals.
Reasons to Buy
Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Crinetics Pharmaceuticals
Curium US
Lantheus Holdings
Eli Lilly
AtaiBeckley
The Procter & Gamble
Thorne Research
Merida Biosciences
Supernus Pharmaceuticals
indivior pharmaceuticals
Telix Pharmaceuticals
ITM Isotope Technologies Munich
Forte Biosciences
Samsung Biologics
PolyPeptide Group
Novartis
Myricx Pharma
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports